Position in NTLA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,140,900
-$1,737,940 QoQ
Shares Held
245,000
+12.4% QoQ
Ownership
0.175%
of shares outstanding
% of Portfolio
0.42%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NTLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Opaleye Management Inc. holds $427,835,777 across 44 Biotechnology names. NTLA ranks #34 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SLGL |
Sol-Gel Technologies Ltd.
|
500,000 | $39,610,000 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
390,000 | $32,826,300 | |
| 3 | IRON |
Disc Medicine, Inc.
|
421,000 | $26,918,740 | |
| 4 | URGN |
UroGen Pharma Ltd.
|
1,430,000 | $25,711,400 | |
| 5 | CBIO |
Crescent Biopharma, Inc.
|
1,312,615 | $24,112,737 | |
| 6 | STOK |
Stoke Therapeutics, Inc.
|
700,000 | $22,792,000 | |
| 7 | RZLT |
Rezolute, Inc.
|
6,300,000 | $19,215,000 | |
| 8 | MGTX |
MeiraGTx Holdings plc
|
2,123,259 | $18,387,422 |
All Filings in NTLA
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,140,900 | 245,000 | Shares | Sole | 2026-05-15 | |
| 2024-06-30 | $4,878,840 | 218,000 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $7,015,050 | 255,000 | Shares | Sole | 2024-05-29 | |
| 2023-12-31 | $3,018,510 | 99,000 | Shares | Sole | 2024-02-14 | |
| 2023-06-30 | $4,893,600 | 120,000 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||